BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peláez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther 2018;9:521-43. [PMID: 29411291 DOI: 10.1007/s13300-018-0374-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Bhadada SK, Pal R. Post-liver transplantation diabetes mellitus — a clinical challenge for diabetologists? Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-00955-3] [Reference Citation Analysis]
2 Willuweit K, Frey A, Hörster A, Saner F, Herzer K. Real-World Administration of Once-Daily MeltDose® Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation. J Clin Med 2020;10:E124. [PMID: 33396492 DOI: 10.3390/jcm10010124] [Reference Citation Analysis]
3 Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, OʼGrady J, Watt KD. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation 2019;103:57-67. [PMID: 30335694 DOI: 10.1097/TP.0000000000002485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
4 Congly SE. Is Diabetes a Risk Factor for Malignancy Post-Transplant in Liver Transplant Recipients? Ann Hepatol 2022;:100703. [PMID: 35338011 DOI: 10.1016/j.aohep.2022.100703] [Reference Citation Analysis]
5 Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep 2021;8:376-85. [PMID: 33680863 DOI: 10.1016/j.toxrep.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver Transplantation and Bariatric Surgery: Timing and Outcomes. Liver Transpl. 2018;24:1280-1287. [PMID: 30080949 DOI: 10.1002/lt.25303] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
7 Chin YH, Tan HQM, Ng CH, Tan DJH, Lin SY, Huang DQ, Khoo CM, Muthiah MD. A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation. J Clin Med 2021;10:1045. [PMID: 33802465 DOI: 10.3390/jcm10051045] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tejedor-Tejada J, Valenzuela EF, Muñoz RN, Gómez LH, García-Pajares F, Álvarez CA, Sánchez-Martín F, Alonso-Martín C, Sánchez-Antolín G. De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors. Eur J Gastroenterol Hepatol 2021;33:399-406. [PMID: 32317584 DOI: 10.1097/MEG.0000000000001736] [Reference Citation Analysis]
9 Schwarzenbach M, Bernhard FE, Czerlau C, Sidler D. Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures. World J Transplant 2021; 11(7): 254-262 [PMID: 34316450 DOI: 10.5500/wjt.v11.i7.254] [Reference Citation Analysis]
10 Richardson B, Khan MQ, Brown SA, Watt KD, Izzy M. Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. Hepatol Commun 2021. [PMID: 34921530 DOI: 10.1002/hep4.1876] [Reference Citation Analysis]
11 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Shaked A, Loza BL, Van Loon E, Olthoff KM, Guan W, Jacobson PA, Zhu A, Fishman CE, Gao H, Oetting WS, Israni AK, Testa G, Trotter J, Klintmalm G, Naesens M, Asrani SK, Keating BJ. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. Nat Med 2022. [PMID: 35393535 DOI: 10.1038/s41591-022-01758-7] [Reference Citation Analysis]
13 Husen P, Straub K, Willuweit K, Hagemann A, Wedemeyer H, Bachmann HS, Herzer K. SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. Transplant Proc 2019;51:1962-71. [PMID: 31303410 DOI: 10.1016/j.transproceed.2019.03.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chen S, Ma J, Zhu H, Deng S, Gu M, Qu S. Hydroxysafflor yellow A attenuates high glucose-induced human umbilical vein endothelial cell dysfunction. Hum Exp Toxicol 2019;38:685-93. [PMID: 30873871 DOI: 10.1177/0960327119831065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Friman S, Tisone G, Nevens F, Lehner F, Santaniello W, Bechstein WO, Zhuvarel SV, Isoniemi H, Rummo OO, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Trunečka P. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. Transplant Direct 2021;7:e722. [PMID: 34263020 DOI: 10.1097/TXD.0000000000001166] [Reference Citation Analysis]
16 Fatourou EM, Tsochatzis EA. Management of metabolic syndrome and cardiovascular risk after liver transplantation. Lancet Gastroenterol Hepatol. 2019;4:731-741. [PMID: 31387736 DOI: 10.1016/s2468-1253(19)30181-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Chauhan K, Khan A, Chowdhury S, Ross HM, Parra NS, Halegoua-demarzio D. A Comprehensive Review on the Risk of Metabolic Syndrome and Cardiovascular Disease after Liver Transplantation. Livers 2022;2:85-96. [DOI: 10.3390/livers2020006] [Reference Citation Analysis]
18 Engelmann C, Aehling NF, Schob S, Nonnenmacher I, Handmann L, Macnaughtan J, Herber A, Surov A, Kaiser T, Denecke T, Jalan R, Seehofer D, Moche M, Berg T. Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis. Hepatol Commun 2022. [PMID: 35420246 DOI: 10.1002/hep4.1946] [Reference Citation Analysis]
19 Chandrakumaran A, Siddiqui MS. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. Gastroenterol Clin North Am 2020;49:165-78. [PMID: 32033762 DOI: 10.1016/j.gtc.2019.09.005] [Reference Citation Analysis]
20 Dooghaie Moghadam A, Eslami P, Razavi-Khorasani N, Moazzami B, Zahedi-Tajrishi F, Farokhi E, Makhdoomi Sharabiani K, Mansour-Ghanaei A, Mehrvar A, Aghajanpoor Pasha M, Saeedi S, Iravani S. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian J Intern Med 2020;11:346-54. [PMID: 33680375 DOI: 10.22088/cjim.11.4.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Lee Y, Tian C, Lovrics O, Soon MS, Doumouras AG, Anvari M, Hong D. Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases 2020;16:1336-47. [DOI: 10.1016/j.soard.2020.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Lin C, Li Y, Liang S, Tao J, Zhang L, Su Y, Huang Y, Zhao Z, Liu S, Zheng J. Metformin Attenuates Cyclosporine A-induced Renal Fibrosis in Rats. Transplantation 2019;103:e285-96. [DOI: 10.1097/tp.0000000000002864] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Elbahr O, Saleh AA, Bakery LH. PNPLA3 L148M (rs738409) polymorphism as a risk for new onset diabetes mellitus and obesity in non-NASH/cryptogenic living related donor liver transplant recipients. Gene Reports 2020;19:100607. [DOI: 10.1016/j.genrep.2020.100607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Izzy M, VanWagner LB, Lee SS, Altieri M, Angirekula M, Watt KD. Understanding and managing cardiovascular outcomes in liver transplant recipients. Curr Opin Organ Transplant 2019;24:148-55. [PMID: 30676402 DOI: 10.1097/MOT.0000000000000614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Becchetti C, Dirchwolf M, Banz V, Dufour JF. Medical management of metabolic and cardiovascular complications after liver transplantation. World J Gastroenterol 2020; 26(18): 2138-2154 [PMID: 32476781 DOI: 10.3748/wjg.v26.i18.2138] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lee C, Wu M, Chan H, Chen T, Hsu L, Wu M, Cherng Y. The Influence of Diabetes Mellitus on the Risks of End-Stage Kidney Disease and Mortality After Liver Transplantation. Transpl Int 2022;36:10023. [DOI: 10.3389/ti.2022.10023] [Reference Citation Analysis]
27 Grancini V, Resi V, Palmieri E, Pugliese G, Orsi E. Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacol Res. 2019;141:556-573. [PMID: 30690071 DOI: 10.1016/j.phrs.2019.01.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
28 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Douglas SJ, Remily EA, Sax OC, Pervaiz SS, Mohamed NS, Kelemen MN, Delanois RE, Johnson AJ. Primary total hip arthroplasty complications and costs in liver transplant recipients: a matched analysis using a national database. Hip Int 2021;:11207000211037225. [PMID: 34748455 DOI: 10.1177/11207000211037225] [Reference Citation Analysis]
30 Plotogea O, Ilie M, Sandru V, Chiotoroiu A, Bratu O, Diaconu C. Cardiovascular and Metabolic Consequences of Liver Transplantation: A Review. Medicina (Kaunas) 2019;55:E489. [PMID: 31443295 DOI: 10.3390/medicina55080489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Puri P, Kotwal N. An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.010] [Reference Citation Analysis]
32 Coman LI, Coman OA, Bădărău IA, Păunescu H, Ciocîrlan M. Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes. J Clin Med 2021;10:E262. [PMID: 33445629 DOI: 10.3390/jcm10020262] [Reference Citation Analysis]
33 Doumouras AG, Lovrics O, Paterson JM, Sutradhar R, Paszat L, Sivapathasundaram B, Tarride JE, Anvari M. Bariatric Surgery and Breast Cancer Incidence: a Population-Based, Matched Cohort Study. Obes Surg 2022. [PMID: 35212909 DOI: 10.1007/s11695-022-05946-9] [Reference Citation Analysis]
34 Khan MQ, Watt KD. Scientific Relief: When Science and Technology Agree and Lead. Liver Transpl 2021;27:484-5. [PMID: 33522080 DOI: 10.1002/lt.25998] [Reference Citation Analysis]